KU Leuven - Department of Neurosciences, Laboratory for Neuroimmunology, Leuven, Belgium.
Leuven Brain Institute, KU Leuven, Leuven, Belgium.
Ann Neurol. 2020 Apr;87(4):633-645. doi: 10.1002/ana.25691. Epub 2020 Feb 8.
Evidence for a role of microglia in the pathogenesis of multiple sclerosis (MS) is growing. We investigated association of microglial markers at time of diagnostic lumbar puncture (LP) with different aspects of disease activity (relapses, disability, magnetic resonance imaging parameters) up to 6 years later in a cohort of 143 patients.
In cerebrospinal fluid (CSF), we measured 3 macrophage and microglia-related proteins, chitotriosidase (CHIT1), chitinase-3-like protein 1 (CHI3L1 or YKL-40), and soluble triggering receptor expressed on myeloid cells 2 (sTREM2), as well as a marker of neuronal damage, neurofilament light chain (NfL), using enzyme-linked immunosorbent assay and electrochemiluminescence. We investigated the same microglia-related markers in publicly available RNA expression data from postmortem brain tissue.
CHIT1 levels at diagnostic LP correlated with 2 aspects of long-term disease activity after correction for multiple testing. First, CHIT1 increased with reduced tissue integrity in lesions at a median 3 years later (p = 9.6E-04). Second, CHIT1 reflected disease severity at a median 5 years later (p = 1.2E-04). Together with known clinical covariates, CHIT1 levels explained 12% and 27% of variance in these 2 measures, respectively, and were able to distinguish slow and fast disability progression (area under the curve = 85%). CHIT1 was the best discriminator of chronic active versus chronic inactive lesions and the only marker correlated with NfL (r = 0.3, p = 0.0019). Associations with disease activity were, however, independent of NfL.
CHIT1 CSF levels measured during the diagnostic LP reflect microglial activation early on in MS and can be considered a valuable prognostic biomarker for future disease activity. ANN NEUROL 2020;87:633-645.
越来越多的证据表明小胶质细胞在多发性硬化症(MS)的发病机制中起作用。我们在 143 例患者队列中研究了诊断性腰椎穿刺(LP)时小胶质细胞标志物与 6 年后不同疾病活动(复发、残疾、磁共振成像参数)方面的关联。
在脑脊液(CSF)中,我们使用酶联免疫吸附试验和电化学发光法测量了 3 种巨噬细胞和小胶质细胞相关蛋白,即几丁质酶 1(CHIT1)、几丁质酶 3 样蛋白 1(CHI3L1 或 YKL-40)和髓样细胞表达的可溶性触发受体 2(sTREM2),以及神经元损伤标志物神经丝轻链(NfL)。我们使用来自死后脑组织的公共 RNA 表达数据研究了相同的小胶质细胞相关标志物。
在经过多次检验校正后,诊断性 LP 时的 CHIT1 水平与长期疾病活动的 2 个方面相关。首先,CHIT1 随着中位数为 3 年后的病灶组织完整性降低而增加(p=9.6E-04)。其次,CHIT1 反映了中位数为 5 年后的疾病严重程度(p=1.2E-04)。与已知的临床协变量一起,CHIT1 水平分别解释了这 2 个指标变异的 12%和 27%,并且能够区分缓慢和快速的残疾进展(曲线下面积=85%)。CHIT1 是慢性活动与慢性非活动病变的最佳鉴别指标,也是唯一与 NfL 相关的标志物(r=0.3,p=0.0019)。与疾病活动的关联与 NfL 无关。
在 MS 早期诊断性 LP 期间测量的 CSF 中的 CHIT1 水平反映了小胶质细胞的激活,可以被视为未来疾病活动的有价值的预后生物标志物。